Protein phosphatase type 2A, PP2A, is involved in degradation of gp130

Molecular and Cellular Biochemistry

Volumn 269, Issue 1, 2005, Pages 183-187

  Mitsuhashi, Shinya ^a   Shima, Hiroshi ^a   Tanuma, Nobuhiro ^a   Sasa, Sumie ^a   Onoe, Kazunori ^a   Ubukata, Makoto ^a   Kikuchi, Kunimi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

gp130; IL 6; Okadaic acid; PP1; PP2A; Proteasome

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEASOME INHIBITOR; SERINE; STAT3 PROTEIN; TAUTOMYCIN;

ARTICLE; CANCER; CELL STRAIN HEPG2; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEIN TARGETING;

ANTIGENS, CD; CYTOKINE RECEPTOR GP130; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; LEUPEPTINS; MEMBRANE GLYCOPROTEINS; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SERINE; TUMOR CELLS, CULTURED;

EID: 14244260032     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-3089-x     Document Type: Article

References (21)

1. Hirano T, Nakajima K, Hibi M: Signaling mechanisms through gp130: A model of the cytokine system. Cytokine & Growth Factor Reviews 8: 241-252, 1997
2. Ohtani T, Ishihara K, Atsumi T, Yoshida Y, Nishida K, Narimatsu M, Shirogane T, Hibi M, Hirano T: Gp130-mediated signaling as a therapeutic target. Emerg Ther Target 4: 459-479, 2000
3. Chow DC, Brevnova L, He XL, Martick MM, Bankovich A, Garcia KC: A structural template for gp130-cytokine signaling assemblies. Biochim Biophys Acta 1592: 225-0235, 2002
4. Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6: From basic science to medicine. Arthritis Res. Suppl 3: S233-S242, 2002
5. Ernst M, Jenkins BJ: Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20: 23-32, 2004
6. Tanuma N, Shima H, Nakamura K, Kikuchi K: Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin-10-induced JAK-STAT signaling. Blood 98: 3030-3034, 2001
7. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003
8. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78: 106-113, 2003
9. Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003
10. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago, Phase II consortium study. J Clin Oncol 22: 115-119, 2004
11. Tariman JD, Lemoine C: Bortezomib. Clin J Oncol Nurs 7: 687-689, 2003
12. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22: 8386-8393, 2003 10.1038/sj.onc.1207170
13. Gibson RM, Schiemann WP, Prichard LB, Reno JM, Ericsson LH, Nathanson NM: Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling. J Biol Chem 275: 22574-22582, 2000
14. Mitsuhashi S, Shima H, Tanuma N, Matsuura N, Takekawa M, Urano T, Kataoka T, Ubukata M, Kikuchi K: Usage of tautomycetin, a novel inhibitor of protein phosphatase 1 (PP1), reveals that PP1 is a positive regulator of Raf-1 in vivo. J Biol Chem 278: 82-88, 2003
15. Cheng XC, Ubukata M, Isono K: The structure of tautomycetin, a dialkylmaleic anhydride antibiotic. J Antibiot (Tokyo) 43: 890-896, 1990
16. Mitsuhashi S, Shima H, Kawamura T, Kikuchi K, Oikawa M, Ichihara A, Oikawa H: The spiroketals containing a benzyloxymethyl moiety at C8 position showed the most potent apoptosis-inducing activity. Bioorg Med Chem Lett 9: 2007-2012, 1999
17. Mitsuhashi S, Saito N, Watano K, Igarashi K, Tagami S, Shima H, Kikuchi K: Defect of delta-sarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: Calcineurin/ PP2B activity in the heart of J2N-k hamster. J Biochem (Tokyo) 134: 269-276, 2003
18. Kim SE, Ishita A, Shima H, Nakamura K, Yamada Y, Ogawa K, Kikuchi K: Increased expression of NIPP-1 mRNA correlates positively with malignant phenotype in rat hepatomas. Int J Oncol 16: 751-755, 2000
19. Kloeker S, Reed R, McConnell JL, Chang D, Tran K, Westphal RS, Law BK, Colbran RJ, Kamoun M, Campbell KS, Wadzinski BE: Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif 31: 19-33, 2003
20. Fukuda H, Shima H, Vesonder RF, Tokuda H, Nishino H, Katoh S, Tamura S, Sugimura T, Nagao M: Inhibition of protein serine/threonine phosphatases by fumonisin B1, a mycotoxin. Biochem Biophys Res Commun 220: 160-165, 1996
21. Schonthal AH: Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 170: 1-13, 2001